Also found in: Wikipedia.


(con-i-vap-tan) ,


(trade name)


Therapeutic: electrolyte modifiers
Pharmacologic: vasopressin antagonists
Pregnancy Category: C


To increase serum sodium in hospitalized patients with euvolemic or hypervolemic hyponatremia.


Antagonizes vasopressin at V2 receptor sites in renal collecting ducts, resulting in excretion of free water.

Therapeutic effects

Increased serum sodium concentrations.
Improved fluid status.


Absorption: IV administration results in complete bioavailability.
Distribution: Unknown.
Protein Binding: 99% protein bound.
Metabolism and Excretion: Metabolized solely by the CYP3A4 enzyme system. 83% excreted in feces as metabolites, 12% in urine (as metabolites).
Half-life: 5 hr.

Time/action profile

IVunknown12 hrend of infusion


Contraindicated in: Hypersensitivity;Hypovolemic hyponatremia;Concurrent use of ketonconazole, itraconazole, clarithromycin, ritonavir, or indinavir.
Use Cautiously in: Moderate hepatic impairment (↓ dose recommended)Severe renal impairment (not recommended if CCr <30 mL/min); Obstetric / Lactation: Safety not established; Pediatric: Safety not established.

Adverse Reactions/Side Effects

Central nervous system

  • headache (most frequent)
  • confusion
  • insomnia


  • hypertension
  • hypotension


  • diarrhea


  • polyuria

Fluid and Electrolyte

  • dehydration
  • hypokalemia
  • hypomagnesemia
  • hyponatremia


  • infusion reactions (most frequent)


  • fever
  • thirst


Drug-Drug interaction

Blood levels and effects are ↑ by ketoconazole, itraconazole, clarithromycin, ritonavir, or indinavir ; concurrent use is contraindicated.↑ blood levels and may ↑ effects of midazolam, simvastatin, lovastatin, amlodipine, and other drugs metabolized by CYP3A4 ; careful monitoring recommended.May ↑ digoxin levels.


Intravenous (Adults) 20 mg loading dose initially, followed by 20 mg/day as a continuous infusion for 2–4 days. May titrate conivaptan up to 40 mg/day as a continuous infusion if serum sodium is not rising at desired rate. Total duration of therapy should not exceed 4 days.

Hepatic Impairment

(Adults) Moderate hepatic impairment—10 mg loading dose initially, followed by 10 mg/day as a continuous infusion for 2–4 days; may titrate up to 20 mg/day as a continuous infusion if serum sodium is not rising at desired rate.


Premixed infusion: 20 mg/100 mL D5W

Nursing implications

Nursing assessment

  • Monitor injection site during administration. Frequently causes erythema, pain, swelling and phlebitis. May require discontinuation of therapy.
  • Monitor vital signs frequently during therapy. Discontinue therapy if patient becomes hypovolemic and hypotensive. Therapy may be resumed at a reduced dose once patient is euvolemic and no longer hypotensive, if patient remains hyponatremic.
  • Assess neurologic status during administration. Overly rapid rise in serum sodium may cause neurologic sequelae.
  • Lab Test Considerations: Monitor serum sodium concentration frequently during therapy. If serum sodium rises at an undesirably rapid rate (>12 mEq/L/24 hr), discontinue administration of conivaptan. If serum sodium continues to rise, do not resume therapy. If hyponatremia persists or recurs (after discontinuation for rapid rise of serum sodium) and patient has no evidence of neurologic sequelae from rapid increase, conivaptan may be resumed at a reduced dose.
    • May cause hyperglycemia, hypoglycemia, hypokalemia, hypomagnesemia, and hyponatremia.

Potential Nursing Diagnoses

Deficient knowledge, related to medication regimen (Patient/Family Teaching)


  • Intravenous Administration
  • Administer IV through large veins and rotate infusion site every 24 hr to minimize risk if vascular irritation.
  • Loading Dose
  • Intermittent Infusion: Diluent: Premixed containers require no further dilution.Concentration: 0.2 mg/mL.
  • Rate: Administer over 30 min.
  • Continuous Infusion
  • Continuous Infusion: Diluent: Premixed containers require no further dilution.Concentration: 0.2 mg/mL.
  • Rate: Administer continuous infusion at a rate of 20 mg/24 hr. If patient requires 40 mg/24 hr continuous infusion, infuse 20 mg over 12 hr, followed by 20 mg over 12 hr.
  • Additive Incompatibility: Do not admix with LR, furosemide, or combine with any other product in the same IV line or bag.

Patient/Family Teaching

  • Explain purpose of medication to patient.
  • Instruct patient to notify health care professional if pain or redness occurs at infusion site.

Evaluation/Desired Outcomes

  • Restoration of normal fluid and electrolyte balance.
Drug Guide, © 2015 Farlex and Partners
References in periodicals archive ?
About Vaprisol (conivaptan hydrochloride) Injection
Tolvaptan is one of the vaptans and is a selective V2 receptor antagonist, whereas conivaptan is a non-selective V1/V2 receptor antagonist (3,5,6,10).
Conivaptan, one of these [V.sub.IA]/[V.sub.2] receptor antagonists, was approved by the Food and Drugs Administration in 2005 for the treatment of patients with clinical hyponatremia [10].
There are currently two FDA-approved vaptans: conivaptan (Cumberland Pharmaceuticals, Inc., Nashville, Tennessee, USA) is a dual vasopressin-1A/2-receptor antagonist available for IV use, and tolvaptan (TO; Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan) is an oral selective vasopressin-2-receptor antagonist [5, 6].
Vaptans, a selective V2 receptor antagonist (Tolvaptan and Conivaptan) can be safely used for treatment of SIADH in carefully monitored patients [17,18].
Hendrix et al., "Acute hemodynamic effects of conivaptan, a dual [V.sub.1A] and [V.sub.2] vasopressin receptor antagonist, in patients with advanced heart failure," Circulation, vol.
According to Cumberland, Caldolor (ibuprofen) Injection is the first injectable treatment for pain and fever approved in the US; Vaprisol (conivaptan) Injection is used for the treatment of hyponatremia and Omeclamox-Pak for the treatment of H.
Some examples of strong CYP3A4 inhibitors are ketoconazole, itraconazole, posaconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelflnavir, indinavir, boceprevir, telaprevir, telithromycin, and conivaptan.
Due to the involvement of CYP3A4 in all of the NOACs except dabigatran, plasma concentrations of apixaban, edoxaban, and rivaroxaban can become elevated in the presence of strong inhibitors.These strong inhibitors include: ketoconazole, itraconazole, conivaptan,HIV protease inhibitors, and clarithromycin.There are other weaker inhibitors and inducers that were also examined by Mohrien, Oliphant, and Self (2013) in an excellent review of these important drug interactions.
Yeni gelisen vasopressin reseptor antagonistleri olan vaptanlar, intravenoz (conivaptan) ve oral kullanim (tolvaptan, lixivaptan, satavaptan) olanaklari ile son yillarda ovolemik ve hipervolemik hiponatremi tedavisinde ilgi odagi olmuslardir.
It is not recommended to use rivaroxaban concomitantly with combined P-gp and strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, lopinavir, ritonavir, indinavir, and conivaptan) or with combined P-gp and strong CYP3A4 inducers (e.g., carbamazepine, phenytoin, rifampin, and St.